Skip to main content
. Author manuscript; available in PMC: 2014 Dec 12.
Published in final edited form as: J Pediatr Hematol Oncol. 2014 Aug;36(6):413–418. doi: 10.1097/MPH.0000000000000179

Figure 3. Schematic representation of purine nucleoside analogue therapy during ALL treatment.

Figure 3

SR (standard risk) and HR (high risk) back bones are shown above with height of the bars representing relative amounts of 6MP/6TG used during treatment cycles. The solid line represents theoretical outgrowth of NT5C2 mutant clones during maintenance therapy leading to relapse disease.